A new drug before surgery for HR+ HER2- breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have hormone receptor positive, HER2-negative breast cancer (confirmed by biopsy)
- You have at least one tumor that can be seen on a scan or exam
- You feel well enough to do daily activities (ECOG score 0 or 1)
- Your liver, kidneys, and other organs are working well enough
- You are not pregnant, not breastfeeding, and willing to use birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for a certain type of breast cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
This trial tests a new immunotherapy drug (QL1706) combined with hormone therapy for breast cancer that is hormone receptor positive and HER2 negative, but did not respond well to initial chemotherapy. The goal is to see if this combination can shrink tumors before surgery and potentially improve outcomes.
This trial tests a new drug called QL706 combined with chemotherapy, with or without another drug called bevacizumab, for people with cervical cancer that has returned or spread and no longer responds to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
Hear when a new HR-positive/HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.